SCHEMBL5262647

SCHEMBL5262647

C=CC(=O)c1cc(F)c(F)c(F)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 4/20 0.56
CES1 P23141 4/20 0.56
AKT1 P31749 1/20 0.46
ALDH5A1 P51649 1/20 0.45
ABAT P80404 1/20 0.45
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
EGFR P00533 1/20 0.42
TP53 P04637 1/20 0.42
CYP3A4 P08684 1/20 0.42
MAPT P10636 1/20 0.42
PKM P14618 1/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
ALOX12 P18054 1/20 0.42
JAK1 P23458 1/20 0.42
MAPK1 P28482 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5471366 0.79 CES2 (0.54) CES2CES1AKT1ALDH5A1ABAT
SCHEMBL2126134 0.78 CES2 (0.59) CES2CES1AKT1ALDH5A1ABAT
SCHEMBL8836296 0.74 KDM4E (0.49) CES2CES1AKT1ALDH5A1ABAT
SCHEMBL13977393 0.74 HDAC1 (0.56) CES2CES1AKT1ALDH5A1ABAT
SCHEMBL2095495 0.73 CES2 (0.64) CES2CES1MAPK1CA1CA2
SCHEMBL16955382 0.73 CES2 (0.44) CES2CES1
SCHEMBL27864041 0.72 CES2 (0.50) CES2CES1KDM4EMAPTMAPK1
SCHEMBL9693525 0.72 CES2 (0.70) CES2CES1EGFRMAPK1CA1
SCHEMBL2156255 0.72 CES2 (1.00) CES2CES1CA1CA2CA4
SCHEMBL28312590 0.72 CES2 (0.70) CES2CES1ALDH1A1TDP1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104926788-A Substituted piperidin derivative, and pharmaceutical composition containing substituted piperidin derivative and application thereof in antitumor UNIV ZHEJIANG 2015-09-23 CN disclosed
US-20070197590-A1 SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS JANSSEN PHARMACEUTCA N.V. (BE) 2007-08-23 US disclosed
EP-1802602-A1 SUBSTITUTED DIPIPERDINE CCR2 ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-04 EP disclosed
WO-2006036527-A1 SUBSTITUTED DIPIPERDINE CCR2 ANTAGONISTS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197590-A1 SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS CCR2, CCR1, CCR5 CES2 2502/4885CES1 2047/4885AKT1 4816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.